In Brief: Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive Summary
Advanced Tissue Sciences: Premarket approval application submission for the firm's Dermagraft-TC engineered human dermal tissue planned for "the first half of 1996," the company announces Dec. 19. The La Jolla, California company says its 65-patient pivotal clinical trial comparing Dermagraft to cadaver skin for the treatment of severe burns has yielded "statistically significant results" with respect to the trial's primary endpoint -- "the ability of the coverings to adequately prepare the wound beds for successful autograft take." In June, FDA notified ATS that its PMA would receive expedited review ("The Gray Sheet" June 12, In Brief)...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.